Results 171 to 180 of about 80,664 (276)

Profiling of HCAR1 signalling reveals Gαi/o and Gαs activation without β‐arrestin recruitment and the discovery of an allosteric agonist

British Journal of Pharmacology, Volume 183, Issue 10, Page 2219-2235, May 2026.
Abstract Background and Purpose Lactate, historically viewed as a metabolic by‐product, has emerged as a signalling molecule via the G protein–coupled receptor Hydroxycarboxylic Acid Receptor 1 (HCAR1). The receptor is primarily expressed in adipocytes but also found in various other tissues.
Simon Lind, Shane C. Wright, Emilia Gvozdenovic, Kristina Nilsson, Kenneth L. Granberg, Michel Bouvier, Linda C. Johansson   +6 more
wiley   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, Volume 183, Issue 10, Page 2518-2532, May 2026.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

The role of dopamine in the life history of bivalves: a review. [PDF]

Front Zool
Nikishchenko V, Dyachuk V.
europepmc   +1 more source

The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient‐as‐Own‐Control Designs

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT A frequently cited concern regarding patient‐as‐own‐control trial designs in rare disease is the potential for placebo and related effects to inflate apparent treatment efficacy. Whether this concern is disqualifying or manageable has not been systematically evaluated.
Marshall L. Summar, Janet Woodcock
wiley   +1 more source

Differences in the Effect of Dopamine on the Phototransduction Between Lampreys and Jawed Vertebrates. [PDF]

Int J Mol Sci
Nikolaeva DA, Rotov AY, Morina IY, Firsov ML, Romanova IV, Astakhova LA.   +5 more
europepmc   +1 more source

A Scoping Review of Non‐Opioid Therapeutics for Opioid Withdrawal: Translational Relevance to Neonatal Opioid Withdrawal Syndrome (NOWS) Research

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT In the wake of the ongoing opioid epidemic, the incidence of neonatal opioid withdrawal syndrome (NOWS) has surged. While the short‐term effects of NOWS are well‐characterized, long‐term physiological and molecular consequences remain unclear.
Sara L. Mills‐Huffnagle, Oliver M. Lowden, Rhea E. Sullivan, Taryn E. McFadden, Jennifer E. Nyland   +4 more
wiley   +1 more source

The indirect pathway hypothesis of schizophrenia: insights from perinatal asphyxia. [PDF]

Front Physiol
Vázquez-Borsetti P.
europepmc   +1 more source

Influence of low‐dose dopamine on exercise in fibrosing interstitial lung disease

Experimental Physiology, Volume 111, Issue 5, Page 2682-2695, 1 May 2026.
ABSTRACT Fibrotic interstitial lung disease (FILD) is associated with dyspnoea and exercise intolerance. In other cardiorespiratory conditions, heightened carotid body (CB) chemoreflex sensitivity is associated with reduced exercise capacity. We tested the hypothesis that CB chemoreflex inhibition would improve exercise endurance time (EET) and reduce ...
Charlotte Chen, Jui‐Lin Fan, Michael Plunkett, Thalia Babbage, John Kolbe, Julian F. R. Paton, James P. Fisher   +6 more
wiley   +1 more source

Driven by Dopamine: Genetic Insights into Motivation and Performance in Sports and Esports. [PDF]

Genes (Basel)
Majchrzak N, Humińska-Lisowska K, Leońska-Duniec A.   +2 more
europepmc   +1 more source